International Stem Cell Corp. (ISCO) Scheduled to Present at International Society for Cellular Therapy Annual Meeting
International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products, this morning told investors that it has been chosen to deliver an oral presentation on its preclinical studies in Parkinson’s at the 21st annual meeting of the International Society for Cellular Therapy in Las Vegas. ISCO’s chief scientific officer, Ruslan Semechkin, Ph.D., will discuss the data at the “Regeneration and Nervous System Repair” session at 11:45 a.m. on May 30, 2015 in a presentation entitled “Human Parthenogenetic Derived Neural Stem Cells for the Treatment of Parkinson’s Disease.”
ISCO has built an extensive preclinical dataset from a series of GLP and non-GLP studies on human parthenogenetic neural stem cells (hpNSC). The dataset includes safety studies, where hpNSC were transplanted into the brains of healthy animals, and proof-of-principle studies where the cells were transplanted into animals with induced Parkinson’s disease symptoms. The studies show that hpNSCs are well tolerated with no evidence of tumor formation even at very high doses and have the ability to protect and recover neurons, increase dopamine levels and improve the motor function. The Company has submitted a CTX application to the Australian regulatory authorities and plans to begin the phase 1/2a clinical study in Parkinson’s disease within the next few months.
The International Society for Cellular Therapy (ISCT) is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. ISCT is one of the only organizations focused on pre-clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product. Over 1200 international delegates including clinicians, scientists and regulatory experts are expected to attend this year’s meeting.
For more information on ISCO and its hpNSCs, visit www.internationalstemcell.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products, this morning told investors that it has been chosen to deliver an oral presentation on its preclinical studies in Parkinson’s at the 21st annual meeting of the International Society for Cellular Therapy in Las Vegas. ISCO’s chief scientific officer, Ruslan Semechkin, Ph.D., will discuss the data at the “Regeneration and Nervous System Repair” session at 11:45 a.m. on May 30, 2015 in a presentation entitled “Human Parthenogenetic Derived Neural Stem Cells for the Treatment of Parkinson’s Disease.”
ISCO has built an extensive preclinical dataset from a series of GLP and non-GLP studies on human parthenogenetic neural stem cells (hpNSC). The dataset includes safety studies, where hpNSC were transplanted into the brains of healthy animals, and proof-of-principle studies where the cells were transplanted into animals with induced Parkinson’s disease symptoms. The studies show that hpNSCs are well tolerated with no evidence of tumor formation even at very high doses and have the ability to protect and recover neurons, increase dopamine levels and improve the motor function. The Company has submitted a CTX application to the Australian regulatory authorities and plans to begin the phase 1/2a clinical study in Parkinson’s disease within the next few months.
The International Society for Cellular Therapy (ISCT) is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. ISCT is one of the only organizations focused on pre-clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product. Over 1200 international delegates including clinicians, scientists and regulatory experts are expected to attend this year’s meeting.
For more information on ISCO and its hpNSCs, visit www.internationalstemcell.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
